Sequencing Strategies for Metastatic Castration-Resistant Prostate Cancer Therapy
An expert examines sequencing strategies for the treatment of metastatic prostate cancer.
EP: 1.Diagnosing Metastatic Prostate Cancer
EP: 2.Biomarker Testing in Metastatic Prostate Cancer
EP: 3.Treatment Options for Metastatic Prostate Cancer
EP: 4.The Role of PARP Inhibitors in Prostate Cancer
EP: 5.Rucaparib for Prostate Cancer
EP: 6.Advances in Metastatic Castration-Resistant Prostate Cancer
EP: 7.Routinely Ordered Testing for Metastatic Prostate Cancer
EP: 8.Biomarker Testing Protocols for Metastatic Prostate Cancer and What to Look For
EP: 9.BRCA1/2 in Metastatic Prostate Cancer
EP: 10.Systemic Treatment Options for Metastatic Castration-Resistant Prostate Cancer
EP: 11.Selecting Appropriate Treatment and Monitoring Patients on Metastatic Prostate Cancer Therapy
EP: 12.The Role of PARP Inhibitors and Adverse Events in Metastatic Prostate Cancer Therapy
EP: 13.Other Factors Considered When Adding PARP Inhibitors to Metastatic Prostate Cancer Therapy
EP: 14.Patient Access and Metastatic Prostate Cancer Therapy
EP: 15.Sequencing Strategies for Metastatic Castration-Resistant Prostate Cancer Therapy
EP: 16.Exciting Advances in the Therapeutic Space and Clinical Pearls for Treating Metastatic Prostate Cancer
EP: 17.Recap: Recommendations for PARP Inhibitor Use in Prostate Cancer
EP: 18.Recap: Testing and Treating Metastatic Castration-Resistant Prostate Cancer
Matthew Fowler: Given all of the options for men with metastatic castration-resistant prostate cancer, what’s your preferred sequencing strategy?
Alicia Morgans, MD, MPH: That changes for every individual man. As we talked about earlier, it’s going to depend on the cancer, the patient himself, how fit or frail he is, what his comorbid illnesses might be, and the specific characteristics of whether that patient can and wants to access different treatments. Even if the patients start off the same way in metastatic hormone-sensitive disease, every patient that I meet ends up taking their own path and the cancer may progress or respond differently for each individual man. At each decision time point, it’s incumbent on us to have those conversations with our patients and find the right match for each of them. And if we don’t pick the right match, we need to make a change and choose the treatment that’s going to be the right one for them moving forward.
There isn’t a preferred pathway for me. In general, many patients end up getting ADT [androgen deprivation therapy] plus an AR [androgen receptor]-targeted agent early on. If they don’t, they get ADT plus docetaxel chemotherapy early on. In the next line, they’re often switching from either chemotherapy to an AR-targeted agent or from an AR-targeted agent to chemotherapy. But that’s a very vast generalization. It’s absolutely different for every individual patient who comes in.
This transcript has been edited for clarity.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
